Form 4: Ocular Therapeutix Director Leslie J. Williams Receives Significant Equity Grants

Ocular Therapeutix, Inc. Director Leslie J. Williams was granted 14,000 restricted stock units and 44,000 stock options on June 11, 2025, as part of her compensation.

Summary

• Ocular Therapeutix, Inc. Director Leslie J. Williams reported the acquisition of 14,000 shares of common stock in the form of restricted stock units (RSUs) on June 11, 2025.
• These RSUs were granted under the Company's 2021 Stock Incentive Plan and represent a right to receive one share of common stock per RSU.
• The RSUs will vest 100% on the first anniversary of the grant date (June 11, 2026) or immediately prior to the next annual meeting of stockholders occurring after the grant date, contingent on continued service on the board.
• Following this transaction, Leslie J. Williams beneficially owns 51,433 shares of common stock directly.
• Additionally, Leslie J. Williams was granted 44,000 stock options on June 11, 2025, with an exercise price of $8.82 per share and an expiration date of June 10, 2035.
• These stock options will also vest 100% on the first anniversary of the grant date (June 11, 2026) or immediately prior to the next annual meeting of stockholders, subject to continued board service.
• After this transaction, Leslie J. Williams beneficially owns 44,000 stock options directly.

Sentiment

Score: 7

Explanation: The filing reports a routine equity grant to a director, which is a positive for aligning interests but does not indicate significant new operational or financial developments. It's a standard compensation event.

Positives

• The grant of restricted stock units and stock options to Director Leslie J. Williams aligns her interests with those of the shareholders, incentivizing long-term performance and commitment to the company.
• The equity awards are a standard component of director compensation, reflecting ongoing commitment to attracting and retaining qualified board members.

Risks

• The vesting of both the restricted stock units and stock options is contingent upon Leslie J. Williams' continued service on the Company's board of directors.

Future Outlook

The vesting schedule for the granted restricted stock units and stock options indicates an expectation of Leslie J. Williams' continued service on the Ocular Therapeutix, Inc. board of directors for at least one year from the grant date or until the next annual meeting of stockholders.

Industry Context

The granting of equity awards such as restricted stock units and stock options to directors is a common and widely accepted practice within the biotechnology and pharmaceutical industries. This compensation structure is designed to align the interests of board members with those of shareholders, promoting long-term value creation and retention of experienced leadership.

Comparison to Industry Standards

• The compensation structure, involving a mix of restricted stock units and stock options, is consistent with typical equity incentive plans observed across publicly traded companies in the biotechnology sector.
• While specific comparable companies are not detailed in the filing, this type of equity grant is a standard mechanism for director compensation, aiming to incentivize performance and long-term commitment, similar to practices at peers like Regeneron Pharmaceuticals or Biogen, which frequently utilize equity-based compensation for their executives and directors.

Corporate Governance

Related Party Transactions

• The grant of 14,000 restricted stock units and 44,000 stock options to Leslie J. Williams, a director of Ocular Therapeutix, Inc., constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with those of the shareholders, potentially leading to decisions that enhance long-term shareholder value.
• Employees: While not directly impacting employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.

Next Steps

• Vesting of 14,000 restricted stock units on June 11, 2026, or prior to the next annual meeting of stockholders, subject to continued service.
• Vesting of 44,000 stock options on June 11, 2026, or prior to the next annual meeting of stockholders, subject to continued service.
• Potential exercise of stock options by Leslie J. Williams at an exercise price of $8.82 per share, anytime between vesting and the expiration date of June 10, 2035.

Key Dates

Keywords

Ocular Therapeutix, OCUL, Form 4, Insider Transaction, Stock Grant, Restricted Stock Units, Stock Options, Director Compensation, Equity Incentive Plan, Leslie J. Williams